Cite this answer
Atrial Natriuretic Peptide: quick citable summary
Atrial Natriuretic Peptide is listed by PeptaHub as a other peptide with a prescription legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Atrial Natriuretic Peptide: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/atrial-natriuretic-peptide. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/atrial-natriuretic-peptide.
What is Atrial Natriuretic Peptide?
Nesiritide (Natrecor) is an FDA-approved recombinant human B-type natriuretic peptide used intravenously for acutely decompensated heart failure. It reduces preload and afterload through NPR-A receptor-mediated vasodilation, though its clinical role has declined following the ASCEND-HF trial.
Overview
Nesiritide (Natrecor) is an FDA-approved recombinant human B-type natriuretic peptide (BNP-32) structurally identical to the endogenous cardiac hormone. It is used intravenously for the treatment of acutely decompensated heart failure in patients with dyspnea at rest or with minimal activity. As a member of the natriuretic peptide family that includes ANP, it reduces preload, afterload, and promotes natriuresis.
Mechanism of action
Nesiritide binds to natriuretic peptide receptor A (NPR-A), a transmembrane guanylyl cyclase receptor expressed on vascular smooth muscle, endothelium, kidneys, and cardiac fibroblasts. Ligand binding activates the receptor's intrinsic guanylyl cyclase domain, generating the intracellular second messenger cyclic GMP (cGMP). Elevated cGMP activates protein kinase G (PKG), which phosphorylates myosin light chain phosphatase and reduces intracellular calcium, causing arterial and venous smooth muscle relaxation. This produces balanced vasodilation, reducing both preload (pulmonary capillary wedge pressure) and afterload (systemic vascular resistance) without reflex tachycardia. In the kidney, cGMP-mediated signaling in the collecting duct increases sodium excretion (natriuresis) and promotes diuresis. Nesiritide also suppresses the renin-angiotensin-aldosterone system and attenuates sympathetic nervous system activation, countering the neurohormonal overdrive characteristic of decompensated heart failure.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| acutely decompensated heart failure | intravenous | 2–2 mcg/kg | IV bolus, then 0.01 mcg/kg/min continuous infusion | 2 mcg/kg bolus over 1 minute, then 0.01 mcg/kg/min continuous infusion. Duration typically 24–48 hours. Monitor blood pressure closely; hypotension is the primary dose-limiting effect. Can reduce/omit bolus if systolic BP <100 mmHg. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Atrial Natriuretic Peptide research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? Use the peptide dose unit converter for educational calculation support.
Research summary
Nesiritide received FDA approval in 2001 for acutely decompensated heart failure. The VMAC trial demonstrated significant reductions in pulmonary capillary wedge pressure vs. placebo and non-inferiority to nitroglycerin at 3 hours. Later safety concerns arose from a 2005 meta-analysis suggesting increased 30-day mortality, prompting a boxed warning and the large ASCEND-HF trial (7,141 patients), which showed nesiritide provided modest dyspnea relief but did not reduce mortality or rehospitalization. Use has declined substantially; its role is now largely adjunctive when conventional diuretic-based decongestion is insufficient.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Atrial Natriuretic Peptide for synergistic effects.
Legal status
FDA-approved since 2001 (Natrecor) for acutely decompensated heart failure. Administered by intravenous bolus and continuous infusion in hospital settings with hemodynamic monitoring. Not a controlled substance. Boxed warning regarding hypotension. Use has declined following ASCEND-HF trial results.
Sourcing & access
Prescription required
Atrial Natriuretic Peptide is an FDA-approved prescription medication available through licensed healthcare providers, pharmacies, and label-appropriate access programs; compounded access depends on current FDA shortage status and compounding rules.
Frequently asked questions
Nesiritide, sold as Natrecor, is an FDA-approved recombinant human B-type natriuretic peptide consisting of 32 amino acids that is structurally identical to the endogenous cardiac hormone. It is administered intravenously in hospital settings for acutely decompensated heart failure in patients with dyspnea at rest or with minimal activity, reducing preload, afterload, and promoting natriuresis.
Nesiritide binds natriuretic peptide receptor A, a transmembrane guanylyl cyclase receptor, generating the second messenger cGMP in vascular smooth muscle, endothelium, and kidneys. The resulting protein kinase G activation drives balanced arterial and venous dilation that reduces preload and afterload without reflex tachycardia, while also promoting natriuresis and suppressing the renin-angiotensin-aldosterone system and sympathetic overdrive.
Use has declined substantially after the 7,141-patient ASCEND-HF trial showed nesiritide produced only modest dyspnea relief with no reduction in mortality or rehospitalization, following earlier 2005 meta-analysis safety concerns that prompted a boxed warning. Nesiritide's role is now largely adjunctive, reserved for cases where conventional diuretic-based decongestion is insufficient or when invasive hemodynamic targets cannot be reached otherwise.
Hypotension is the primary dose-limiting effect and carries a boxed warning; the 2 mcg per kg bolus can be reduced or omitted if systolic blood pressure is below 100 mmHg. Other reported side effects include headache, nausea, bradycardia, dizziness, back pain, and increased serum creatinine. Nesiritide is administered only in hospital settings with continuous hemodynamic monitoring during the 24 to 48 hour infusion.